Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.38 |
| ▸ | HTR2A | P28223 | 9/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 9/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24775371 | 0.73 | KDM4E (0.34) | ALDH1A1 | |
| SCHEMBL2865914 | 0.70 | HTR2C (0.34) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL10679520 | 0.70 | HTR2C (0.34) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2161211 | 0.69 | HTR2C (0.57) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL20544769 | 0.68 | HTR2C (0.55) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL10682862 | 0.67 | HTR2C (0.35) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9808049 | 0.66 | HTR2C (0.38) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL10682422 | 0.64 | HTR2C (0.30) | HTR2CHTR2AHTR2B | |
| SCHEMBL29977318 | 0.62 | — | — | |
| SCHEMBL30282930 | 0.62 | HTR2C (0.42) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262807-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116829151-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-5026853-A | Sleep and cardiovascular disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-06-25 | — | — | US | disclosed |
| US-4968684-A | N-ARYL-PIPERAZINEALKANAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-11-06 | — | — | US | disclosed |
| US-4880808-A | SEDATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-11-14 | — | — | US | disclosed |
| US-4766125-A | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-23 | — | — | US | disclosed |
| EP-0068544-B1 | NOVEL N-ARYL-PIPERAZINEALKANAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-06-03 | — | — | EP | disclosed |